Title:Future Directions in Anxiolytic Therapy: A Comprehensive Review of Novel Targets and Strategies
Volume: 22
Issue: 2
Author(s): Mahima, Avijit Mazumder*Bhavani Pentela
Affiliation:
- Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Plot no. 19,
Knowledge Park- II, Greater Noida, Uttar Pradesh, 201306, India
Keywords:
Anxiety disorders, novel therapeutic targets, anxiety treatment advancements, microbiome modulation, personalized medicine, digital therapeutics, herbal therapy, peptide-based therapy, gene therapy, combination therapy.
Abstract:
Background: With 301 million cases worldwide, anxiety disorders represent a serious
public health concern. Many people endure ongoing distress while receiving several treatments
because of the drawbacks of traditional therapy, such as adverse effects, dependence, and inconsistent
efficacy. This emphasizes the absolute need for novel treatment approaches.
Objective: This review examines emerging pharmacological and non-pharmacological strategies
for anxiety disorders, assessing existing and developing therapeutic options while examining the
drawbacks of conventional therapies.
Methods: A comprehensive literature review was carried out using the NIH, PubMed, and
Google Scholar databases. Studies from 2020-2025 were given priority in the inclusion criteria,
with a few supporting references from earlier years. Personalized medicine, combination therapy,
non-pharmacological interventions, and novel anxiolytic targets, etc., were among the keywords
used.
Results: Conventional therapies, including benzodiazepines, SSRIs, and SNRIs, are still the major
choices, but they have significant disadvantages. The protein kinase pathway, endocannabinoid
and orexin systems, NK1R antagonists, and microbiome modulation are examples of
emerging targets. Emerging strategies that show preliminary promise include digital therapeutics,
gene therapy, optogenetics, personalized medicine, combination therapy, herbal therapy,
and peptide-based medicines (e.g., NPY, NPS, oxytocin analogs, CRF, vasopressin, and melanocortin
receptor antagonist). Several of these approaches modulate key neural circuits, such as the
involvement of the amygdala–prefrontal cortex axis, via the HPA axis, and biomarker-informed
personalization, among others; yet many remain in early-phase or preclinical investigation.
However, limited comparative data exist between these novel strategies and standard therapies,
underlining the need for rigorous head-to-head evaluations.
Conclusion: Advances in molecular neuroscience and precision medicine offer potential alternatives
to conventional treatments. However, most emerging therapies require further clinical validation,
large-scale trials, and translational refinement before they can be integrated into realworld
decision-making for anxiety disorders.
